Novartis Ag

Sandoz Gmbh

Novartis Corporation

First Fidelity Bank, National Association, New Jersey

Thomas Cavanak

Moise Azria

Ulrich Posanski

Alan Harris

Pharmaceutical compositions comprising a cyclosporin as active ingredient, a fatty acid triglyceride, a glycerol fatty acid partial ester or propylene glycol or sorbitol complete or partial ester, preferably, and a tenside having an HLB of at least 10.

Cyclosporin galenic forms

The invention provides a pharmaceutical composition comprising a somatostatin analogue, and its use in the treatment of breast cancer. The pharmaceutical composition preferably contains lactic acid in addition to the somatostatin analogue and is better tolerated when administered by injection.

Somatostatin analogue composition and use in treating breast cancer

Pharmaceutical compositions for nasal administration comprising i) a calcitonin, and ii) benzalkonium chloride, and/or iv) a surfactant, suitable for application to the nasal mucosa, in iii) a liquid diluent or carrier, suitable for application to the nasal mucosa. The compositions are suitably adapted for administration in the form of a nasal spray.

Galenic compositions comprising calcitonin and their use

The invention provides a pharmaceutical composition containing a somatostatin analogue, and its use in the treatment of breast cancer. The pharmaceutical composition preferably contains lactic acid in addition to the somatostatin analogue and is better tolerated when administered by injection.

The present invention provides a nasal pharmaceutical composition comprising as active agent a compound of formula I, ##STR1## wherein R.sub.1 is hydrogen or halogen,

Certain ergot peptide alkaloids administered to the nasal mucosa

Lyophylisates comprising bromocriptine or an acid addition salt thereof capable of reconstitution in an isotonic vehicle to provide a stable formulation for occular instillation, useful e.g. in the treatment of glaucoma. Typical lyophylisates in accordance with the invention comprise: a lyophylisable acid, e.g. methane sulfonic acid, an acid addition salt of bromocriptine with said acid, e.g. bromocriptine mesylate, benzalkonium chloride and a lyophylisate matrix material.

Occular formulation comprising bromocriptine

The present invention provides a nasal or pulmonary pharmaceutical composition comprising as active agent a compound of formula I, ##STR1## wherein R.sub.1 is hydrogen or halogen,

The present invention provides a pharmaceutical composition comprising a pharmacologically active monocyclic peptide and a carrier comprising at least one of the following components:

Growing community of inventors

Biel-Benken, Switzerland

Thomas Cavanak